CompletedNot Applicable

Cohort Study of Blood Biomarkers for TES

China120 participantsStarted 2021-05-01

Plain-language summary

In this study, high-throughput screening and multi-omics (transcriptomics and proteomics) joint analysis technology will be employed to explore potential CTE/TES biomarkers (RNA and protein) in blood and its exosomes. Thereafter, these biomarkers will be combined with the reported TBI biomarkers to create a novel set of CTE/TES molecular diagnostic signatures. The findings may open a new avenue for the clinical diagnosis of the disease and the future research on its therapeutic strategy.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Athletes and patients with traumatic brain injury
✓. Healthy Volunteers

Exclusion criteria

✕. Athletes and patients with traumatic brain injury
✕. Healthy Volunteers

What they're measuring

Blood level of novel protein biomarkers for CTE/TES

Timeframe: Baseline

Blood level of novel RNA biomarkers for CTE/TES

Timeframe: Baseline

Trial details

NCT IDNCT04928534

SponsorTianjin Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-01

View on ClinicalTrials.gov More Chronic Traumatic Encephalopathy trials